Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 4,242 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Deficiency Disorder Clear all
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

NCT05470491
View directory record Official record
Conditions
HIV, Hematologic Malignancies
Interventions
RIC, GVHD prophylaxis, allo HCT, Plerixafor, Maraviroc
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 3 Interventional

The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs

NCT00002368
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine, Lamivudine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
13 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
53
States / cities
Montgomery, Alabama • Los Angeles, California • Palo Alto, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 8:29 AM EDT
Completed No phase listed Observational Results available

Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

NCT00851799
View directory record Official record
Conditions
HIV Infection
Interventions
Emtricitabine/tenofovir disoproxil fumarate, Ritonavir, Atazanavir, Raltegravir, Darunavir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
26
States / cities
Los Angeles, California • San Francisco, California • Torrance, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects

NCT01220232
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Abacavir/Lamivudine, Lersivirine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 4, 2011 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 2 Interventional Results available

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

NCT00053989
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Fanconi Anemia, Aplastic Anemia
Interventions
anti-thymocyte globulin, graft-versus-tumor induction therapy, sargramostim, therapeutic allogeneic lymphocytes, cyclophosphamide, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, umbilical cord blood transplantation
Biological · Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
4 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 19, 2026, 8:29 AM EDT
Not listed Not applicable Interventional

Tenofovir Disoproxil Fumarate in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drug Combinations

NCT00011089
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir disoproxil fumarate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Foster City, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 8:29 AM EDT
Completed No phase listed Observational

Use of Bromodeoxyuridine to Study White Blood Cell Replication and Survival in HIV-Infected Patients

NCT00001650
View directory record Official record
Conditions
HIV Infection, Acquired Immunodeficiency Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 2 Interventional

Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals

NCT00002189
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Paclitaxel
Drug
Lead sponsor
Baker Norton Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 2 Interventional

Brief Intervention for Drug Misuse in the Emergency Department

NCT01124591
View directory record Official record
Conditions
Substance Abuse Detection, HIV, Hepatitis B, Hepatitis C, Brief Intervention, HIV Infections
Interventions
Brief motivational intervention
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
1,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 2 Interventional Results available

Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders

NCT01050855
View directory record Official record
Conditions
Non Malignant Diseases, Immunodeficiencies, Hemoglobinopathies
Interventions
Reduced-Intensity Conditioning
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months to 25 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 19, 2026, 8:29 AM EDT
Withdrawn Not applicable Interventional

Welcoming by Design Pilot: Reducing Structural Stigma by Changing Clinic Systems and Architectural Design

NCT05642676
View directory record Official record
Conditions
Hiv
Interventions
Clinics remodeling
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 19, 2026, 8:29 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings

NCT06854029
View directory record Official record
Conditions
HIV Infections, Opioid Use Disorder, Incarceration; Lens
Interventions
Cabotegravir Injection, Cabotegravir Pill, Buprenorphine injection, Buprenorphine Pill
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 4 Interventional Results available

A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment

NCT00145795
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra + Current Dual NRTI Backbone, Current Regimen
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics

NCT01632995
View directory record Official record
Conditions
HIV Infections
Interventions
FTC 200 mg/TDF 300 mg fixed-dose combination tablet
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
557 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
3
States / cities
San Francisco, California • Washington D.C., District of Columbia • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults

NCT01783977
View directory record Official record
Conditions
HIV Infections
Interventions
DNA-HIV-PT123 vaccine, NYVAC-HIV-PT1 vaccine, NYVAC-HIV-PT4 vaccine, Placebo for DNA-HIV-PT123 vaccine, Placebo for NYVAC-HIV-PT1 vaccine, Placebo for NYVAC-HIV-PT4 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults

NCT00069030
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
7
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Determining an Effective Site (Groin Versus Arm) for Giving HIV Vaccines

NCT00056745
View directory record Official record
Conditions
HIV Infections
Interventions
TBC-3B
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 33 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2007 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Epicutaneous 1-Chloro-2, 4-Dinitrobenzene (DNCB) Patch in HIV Infection.

NCT00002175
View directory record Official record
Conditions
HIV Infections
Interventions
Dinitrochlorobenzene
Drug
Lead sponsor
The Honolulu Medical Group
Other
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Not applicable Interventional

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

NCT00000919
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Hydroxyurea, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
63
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment

NCT00002419
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Amprenavir, Efavirenz, Adefovir dipivoxil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Not applicable Interventional

Theory-based HIV Disclosure Intervention for Parents

NCT04051177
View directory record Official record
Conditions
HIV/AIDS, Disclosure
Interventions
Interactive Communication with Openness, Passion, and Empowerment "ICOPE", Nutrition Curriculum
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
791 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 19, 2026, 8:29 AM EDT
Completed No phase listed Observational

HLA-B*5701 And Hypersensitivity To Abacavir

NCT00373945
View directory record Official record
Conditions
HIV Infection
Interventions
Observational Study
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
55
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 18, 2009 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat

NCT01837719
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1 (HIV-1)
Interventions
Atazanavir, Cobicistat, Atazanavir/Cobicistat FDC
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 49 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2014 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults

NCT01103687
View directory record Official record
Conditions
HIV Infections
Interventions
Ad26.ENVA.01 (rAd26), Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2017 · Synced Oct 19, 2026, 8:29 AM EDT